Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26564577 | 0.94 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2LPAR3LPAR2 | |
| SCHEMBL26564576 | 0.88 | ALDH1A1 (0.30) | ALDH1A1CNR1CNR2 | |
| SCHEMBL26564597 | 0.84 | ALDH1A1 (0.35) | ALDH1A1CNR1CNR2LPAR3LPAR2 | |
| SCHEMBL26564612 | 0.83 | LPAR2 (0.32) | LPAR3LPAR2LPAR1 | |
| SCHEMBL26564621 | 0.80 | LPAR3 (0.37) | ALDH1A1CNR1CNR2LPAR3LPAR2 | |
| SCHEMBL26564571 | 0.78 | LPAR2 (0.43) | ALDH1A1CNR1CNR2LPAR3LPAR2 | |
| SCHEMBL26564628 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL26564625 | 0.78 | ADRB2 (0.38) | ALDH1A1 | |
| SCHEMBL16130809 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2LPAR3LPAR2 | |
| SCHEMBL26564569 | 0.74 | DNM1 (0.48) | LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | ALDH1A1 331/4885CNR1 3557/4885CNR2 3860/4885 |
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | SGMS1, SGMS2, LIPA | ALDH1A1 258/4885CNR1 3207/4885CNR2 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.